Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
- 544 Downloads
Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic pathways by binding to proapoptotic death receptor (DR) 4 and DR5. The purpose of this study was to evaluate the efficacy and safety of dulanermin combined with vinorelbine and cisplatin (NP) as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Experimental design Patients were randomly assigned to receive NP chemotherapy (vinorelbine 25 mg/m2 on days 1 and 8 and cisplatin 30 mg/m2 on days 2 to 4) for up to six cycles plus dulanermin (75 μg/kg on days 1 to 14) or placebo every three weeks until disease progression, intolerable toxicity, or withdrawal of consent. The primary end point was progression-free survival (PFS), and the secondary end points included objective response rate (ORR), overall survival (OS), and safety evaluation. Results Between October 2009 and June 2012, 452 untreated patients with stage IIIB to IV NSCLC were randomly assigned to receive dulanermin plus NP (n = 342) and placebo plus NP (n = 110). Median PFS was 6.4 months in the dulanermin arm versus 3.5 months in the placebo arm (hazard ratio (HR), 0.4034; 95% CI, 0.3181 to 0.5117, p < 0.0001). ORR was 46.78% in the dulanermin arm versus 30.00% in the placebo arm (p = 0.0019). Median OS was 14.6 months in the dulanermin arm versus 13.9 months in the placebo arm (HR, 0.94; 95% CI, 0.74 to 1.21, p = 0.64). The most common grade ≥ 3 adverse events (AEs) were oligochromemia, leukopenia, neutropenia, and oligocythemia. Overall incidence of AEs, grade ≥ 3 AEs, and serious AEs were similar across the two arms. Conclusion Addition of dulanermin to the NP regimen significantly improved PFS and ORR. However, our results showed that the combination of dulanermin with chemotherapy had a synergic activity and favorable toxic profile in the treatment of patients with advanced NSCLC.
KeywordsPhase III Dulanermin NSCLC Progression-free survival Objective response rate
The authors thank the patients who participated in this study and express appreciation of the assistance and understanding of their families. The authors also thank the study-site staff for their support.
The work was also funded by Shanghai Biomedical Technology fund (grant number 08431901100), National Innovation Fund (grant number 10C26213100701), and National Science and Technology Major Project fund (grant number 2010ZX09401-301).
Compliance with ethical standards
Conflict of interest
All authors received research funding from Gebaide Biotechnology Co., Ltd. for conducting the study and preparing this report. No potential conflicts of interest were disclosed.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Written informed consent was obtained from all individual patients included in the study.
- 1.American Cancer Society (2012) Non-small cell lung cancer 2012. American Cancer Society, AtlantaGoogle Scholar
- 2.American Cancer Society (2011) Cancer facts and figures 2011. American Cancer Society, AtlantaGoogle Scholar
- 3.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2011) Non-small cell lung cancer (version1.). Google Scholar
- 8.Fan K, Luo L, Liu HH (2011) Research advance in TNF related apoptosis inducing ligand. J Chongqing Univ Technol 2:165–170Google Scholar
- 18.Zhou SY, Chen SS, Liu P, Luo P, Xing PY et al (2007) Phase I clinical tolerance trial of recombinant human Apo-2 ligand in patients with advanced cancer. Chi J New Drugs 16:71–75Google Scholar